Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background and Objective: Dabigatran etexilate is an oral direct thrombin inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Following oral administration, dabigatran etexilate is rapidly absorbed and converted into its active form, dabigatran. The aim of this study was to investigate the effect of renal impairment on the pharmacokinetics and pharmacodynamics of dabigatran following administration of a single oral dose of dabigatran etexilate in subjects with renal impairment (150 mg) or end-stage renal disease (ESRD) on maintenance haemodialysis (50 mg).
Methods: This open-label, parallel-group, single-centre study enrolled 23 subjects with mild, moderate or severe renal impairment (creatinine clearance >50 to ≤80, >30 to ≤50 and ≤30 mL/min, respectively), 6 patients with ESRD and 6 healthy subjects. Blood and urine samples were collected up to 96 hours after dosing for determination of dabigatran pharmacokinetic and pharmacodynamic parameters.
Results: Compared with the values in healthy subjects, the area under the plasma concentration-time curve from time zero to infinity (AUC∞) values were 1.5-, 3.2- and 6.3-fold higher in subjects with mild, moderate and severe renal impairment. Changes in the maximum plasma concentration (Cmax) were modest, and the time to reach the Cmax was unchanged. In subjects with severe renal impairment, the mean terminal elimination half-life was doubled (28 hours vs 14 hours for control). The AUC for prolongation of pharmacodynamic parameters (the activated partial thromboplastin time and ecarin clotting time) increased in line with the pharmacokinetic changes. In patients with ESRD, the dose-normalized AUC∞ was approximately twice the value in the control group. Haemodialysis removed 62–68% of the dose. Dabigatran etexilate was well tolerated in all groups.
Conclusions: Exposure to dabigatran is increased by renal impairment and correlates with the severity of renal dysfunction. A decrease in the dose and/or an increase in the administration interval in these patients may be appropriate. In patients with ESRD, dabigatran can be partly removed from the plasma by haemodialysis.
- Blech, S., Ebner, T., Ludwig-Schwellinger, E. (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: pp. 386-99 CrossRef
- Stangier, J., Rathgen, K., Stähle, H. (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: pp. 292-303 CrossRef
- Stangier, J., Eriksson, B.I., Dahl, O.E. (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45: pp. 555-63 CrossRef
- Stangier, J., Stähle, H., Rathgen, K. (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47: pp. 47-59 CrossRef
- Stangier, J. (2008) Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47: pp. 285-95 CrossRef
- Garnett, C., Liesenfeld, K.H., Tillmann, C. (2003) Modelling and clinical trial simulation in drug development: the effect of renal impairment on the exposure-response relationship of a direct thrombin inhibitor, BIBR 1048, in hip replacement [abstract].
- Troconiz, I.F., Tillmann, C., Liesenfeld, K.H. (2007) Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin Pharmacol 47: pp. 371-82 CrossRef
- Eriksson, B.I., Dahl, O.E., Rosencher, N. (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370: pp. 949-56 CrossRef
- Eriksson, B.I., Dahl, O.E., Rosencher, N. (2007) Oral dabigatran etexilate vs sub-cutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Hae-most 5: pp. 2178-85 CrossRef
- Ginsberg, J.S., Davidson, B.L., Comp, P.C. (2009) Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 24: pp. 1-9 CrossRef
- Ezekowitz, M.D., Connolly, S., Parekh, A. (2009) Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 157: pp. 805-10 CrossRef
- Center for Drug Evaluation and Research, US FDA. Guidance for industry: pharmacokinetics in patients with impaired renal function — study design, data analysis, and impact on dosing and labeling [online]. Rockville (MD): FDA, 1998 May. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072127.pdf [Accessed 2009 Dec 17]
- Levey, A.S., Bosch, J.P., Lewis, J.B. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: pp. 461-70
- Eriksson, U.G., Johansson, S., Attman, P.O. (2003) Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 42: pp. 743-53 CrossRef
- Hervé, F., Urien, S., Albengres, E. (1994) Drug binding in plasma: a summary of recent trends in the study of drug and hormone binding. Clin Pharmacokinet 26: pp. 44-58 CrossRef
- Zini, R., Riant, P., Barre, J. (1990) Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part I). Clin Pharmacokinet 19: pp. 147-59 CrossRef
- Zini, R., Riant, P., Barre, J. (1990) Disease-induced variations in plasma protein levels: implications for drug dosage regimens (part II). Clin Pharmacokinet 19: pp. 218-29 CrossRef
- Boehringer Ingelheim Pharma GmbH & Co. KG. Pradaxa: summary of product characteristics. Ingelheim am Rhein: Boehringer Ingelheim Pharma GmbH & Co. KG, 2008 Mar [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/pradaxa/emea-combined-h829en.pdf [Accessed 2010 Jan 15]
- Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
Volume 49, Issue 4 , pp 259-268
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors